ACLX-001 is under clinical development by Arcellx and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ACLX-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ACLX-001 is under development for the treatment of multiple myeloma, relapsed multiple myeloma and refractory multiple myeloma. The drug candidate is administered through the parenteral route. The drug candidate comprises autologous antigen receptor complex (ARC) T cells and a bivalent SparX (soluble protein antigen-receptor X-linker) protein targeting BCMA. The drug candidate acts by targeting cells expressing BCMA. The drug candidate is being developed based on ARC-SparX platform.
It was under development for treatment of autoimmune disease
Arcellx is a biopharmaceutical company which develops, manufactures and markets novel and adaptive cell therapies for the treatment of cancer, acute myeloid leukemia, solid tumors and autoimmune diseases. Arcellx is headquartered in Gaithersburg, Maryland, the US.
For a complete picture of ACLX-001’s drug-specific PTSR and LoA scores, buy the report here.